Anti-CGRP Migraine Antibodies Remain Effective at 2 Years: Large European Study
Two-year results from the EUREkA cohort show sustained effectiveness of anti-CGRP monoclonal antibodies for migraine, with identifiable factors predicting long-term persistence.
Quick Facts
What This Study Found
Anti-CGRP monoclonal antibodies demonstrated sustained effectiveness at 24 months with significant reduction in monthly headache days, and baseline factors predicting 2-year treatment persistence were identified.
Key Numbers
How They Did This
Prospective observational multicenter registry study (EUREkA cohort) analyzing anti-CGRP MAb effectiveness and persistence factors at 24 months.
Why This Research Matters
Long-term effectiveness data justifies continued insurance coverage and helps patients commit to treatment knowing it maintains efficacy over 2 years.
The Bigger Picture
This provides the long-term real-world evidence needed to establish anti-CGRP therapies as durable first-line migraine prevention treatments.
What This Study Doesn't Tell Us
Observational registry — no control group. Survivor bias may inflate effectiveness if non-responders dropped out early.
Questions This Raises
- ?Do benefits continue beyond 2 years?
- ?Which baseline factors most strongly predict long-term success?
Trust & Context
- Key Stat:
- Sustained at 24 months Anti-CGRP antibodies continued reducing headache days after 2 years of treatment
- Evidence Grade:
- Prospective multicenter registry — strong real-world evidence for long-term effectiveness.
- Study Age:
- Published in 2026; provides mature long-term data on anti-CGRP therapies.
- Original Title:
- Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.
- Published In:
- Neurology, 106(4), e214659 (2026)
- Authors:
- Caronna, Edoardo(2), Mas-de-Les-Valls, Rut, Egeo, Gabriella, Millán Vázquez, Manuel, Nieves-Castellanos, Candela, Portocarrero-Sánchez, Leonardo, Vaghi, Gloria, Rodríguez-Montolio, Joana, Jaimes, Alex, Muñoz-Vendrell, Albert, Oliveira, Renato, Polanco, Marcos, González Osorio, Yesica, Canales, Javiera, Ornello, Raffaele, Thunstedt, Cem, Fernández-Lázaro, Iris, Husøy, Andreas, Sánchez-Soblechero, Antonio, Nunes Vicente, Beatriz, Riesco, Nuria, Flores Pina, Belén, Fernandes, Catarina, Lopez, Alberto Andres, Martins-Silva, Elisa, Budrewicz, Sławomir, Gallardo, Víctor José, Gómez Dabó, Laura, Torres-Ferrus, Marta, Alpuente, Alicia, Torelli, Paola, Aurilia, Cinzia, Lamas, Raquel, Ruiz Castrillo, Maria José, De Icco, Roberto, Sances, Grazia, Broadhurst, Sarah, Winstanley, Jed, Gómez, Andrea, Campoy, Sergio, Marques, Inês, Parreira, Elsa, Gárate, Gabriel, Pascual, Julio, Guerrero Peral, Angel Luis, Caponnetto, Valeria, Straube, Andreas, Gonzalez-Martinez, Alicia, Quintas, Sonia, Sánchez-Del-Río, Margarita, Tronvik, Erling, Venegas Pérez, Begoña, Oterino Duran, Agustín, Rodrigues, Miguel, Cevoli, Sabina, Colombo, Bruno, Trimboli, Michele, Frediani, Fabio, d'Onofrio, Florindo, Aguggia, Marco, Salerno, Antonio, Carnevale, Antonio, Zucco, Maurizio, Albanese, Maria, Finocchi, Cinzia, Ranieri, Angelo, Zoroddu, Francesco, Autunno, Massimo, Sanahuja, Jordi, Waliszewska-Prosół, Marta, Pereira, Liliana, Layos-Romero, Almudena, Luzeiro, Isabel, Dorado, Laura, Alvarez-Escudero, Rocio, Martins, Isabel Pavao, Sundal, Christina, Irimia, Pablo, Lozano Ros, Alberto, Gago-Veiga, Ana Beatriz, Juanes, Fernando Velasco, Ruscheweyh, Ruth, Sacco, Simona, García-Azorín, David, González-Quintanilla, Vicente, Gil-Gouveia, Raquel Santos, Huerta Villanueva, Mariano, Rodríguez-Vico, Jaime, Lasaosa, Sonia Santos, Ghadri-Sani, Mona, Tassorelli, Cristina, Díaz De Terán Velasco, Francisco Javier, Diaz-Insa, Samuel, González Oria, Carmen, Barbanti, Piero, Pozo-Rosich, Patricia
- Database ID:
- RPEP-14939
Evidence Hierarchy
Frequently Asked Questions
Do anti-CGRP migraine drugs keep working long-term?
Yes — this 2-year study from a large European registry shows anti-CGRP antibodies maintain their effectiveness in reducing headache days at 24 months.
How do I know if anti-CGRP therapy will work for me long-term?
This study identified baseline factors that predict who will continue treatment for 2 years. Your doctor can assess these factors to help set realistic expectations for your migraine prevention.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14939APA
Caronna, Edoardo; Mas-de-Les-Valls, Rut; Egeo, Gabriella; Millán Vázquez, Manuel; Nieves-Castellanos, Candela; Portocarrero-Sánchez, Leonardo; Vaghi, Gloria; Rodríguez-Montolio, Joana; Jaimes, Alex; Muñoz-Vendrell, Albert; Oliveira, Renato; Polanco, Marcos; González Osorio, Yesica; Canales, Javiera; Ornello, Raffaele; Thunstedt, Cem; Fernández-Lázaro, Iris; Husøy, Andreas; Sánchez-Soblechero, Antonio; Nunes Vicente, Beatriz; Riesco, Nuria; Flores Pina, Belén; Fernandes, Catarina; Lopez, Alberto Andres; Martins-Silva, Elisa; Budrewicz, Sławomir; Gallardo, Víctor José; Gómez Dabó, Laura; Torres-Ferrus, Marta; Alpuente, Alicia; Torelli, Paola; Aurilia, Cinzia; Lamas, Raquel; Ruiz Castrillo, Maria José; De Icco, Roberto; Sances, Grazia; Broadhurst, Sarah; Winstanley, Jed; Gómez, Andrea; Campoy, Sergio; Marques, Inês; Parreira, Elsa; Gárate, Gabriel; Pascual, Julio; Guerrero Peral, Angel Luis; Caponnetto, Valeria; Straube, Andreas; Gonzalez-Martinez, Alicia; Quintas, Sonia; Sánchez-Del-Río, Margarita; Tronvik, Erling; Venegas Pérez, Begoña; Oterino Duran, Agustín; Rodrigues, Miguel; Cevoli, Sabina; Colombo, Bruno; Trimboli, Michele; Frediani, Fabio; d'Onofrio, Florindo; Aguggia, Marco; Salerno, Antonio; Carnevale, Antonio; Zucco, Maurizio; Albanese, Maria; Finocchi, Cinzia; Ranieri, Angelo; Zoroddu, Francesco; Autunno, Massimo; Sanahuja, Jordi; Waliszewska-Prosół, Marta; Pereira, Liliana; Layos-Romero, Almudena; Luzeiro, Isabel; Dorado, Laura; Alvarez-Escudero, Rocio; Martins, Isabel Pavao; Sundal, Christina; Irimia, Pablo; Lozano Ros, Alberto; Gago-Veiga, Ana Beatriz; Juanes, Fernando Velasco; Ruscheweyh, Ruth; Sacco, Simona; García-Azorín, David; González-Quintanilla, Vicente; Gil-Gouveia, Raquel Santos; Huerta Villanueva, Mariano; Rodríguez-Vico, Jaime; Lasaosa, Sonia Santos; Ghadri-Sani, Mona; Tassorelli, Cristina; Díaz De Terán Velasco, Francisco Javier; Diaz-Insa, Samuel; González Oria, Carmen; Barbanti, Piero; Pozo-Rosich, Patricia. (2026). Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.. Neurology, 106(4), e214659. https://doi.org/10.1212/WNL.0000000000214659
MLA
Caronna, Edoardo, et al. "Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.." Neurology, 2026. https://doi.org/10.1212/WNL.0000000000214659
RethinkPeptides
RethinkPeptides Research Database. "Long-Term Effectiveness and Persistence Factors of Anti-CGRP..." RPEP-14939. Retrieved from https://rethinkpeptides.com/research/caronna-2026-longterm-effectiveness-and-persistence
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.